European Medical Technology and Life Sciences Valuations Are Low, and the Bar for Earnings Recovery Is Low

Overview

This report reviews first-quarter 2026 results for the European medical technology and life sciences sector. Overall, revenue growth for most companies was in line with or slightly below expectations, and demand recovery remains uneven; EPS was relatively better, but many beats were driven by non-operating factors. Although quarterly results have not broadly turned stronger, market expectations and investor positioning are already low, and sector valuations are depressed, so even a modest improvement in earnings expectations could trigger a valuation rerating.

Core views

The report's core view is that the sector has not entered a full recovery yet, but the hurdle for recovery is low, making selective allocation appropriate. CDMO, life science consumables, parts of healthcare services, online pharmacies, ophthalmology, and prosthetics and orthotics are more resilient; diagnostics, chronic care, packaging and delivery devices, imaging and radiation therapy, and hearing care still face demand, regulation, inflation, or company-specific issues. Deutsche Bank lists Fresenius SE, Lonza, Ottobock, and Sartorius as its sector favorites.

Analysis framework

The report evaluates investment opportunities by examining first-quarter performance versus market expectations, changes in full-year guidance, earnings estimate revisions, valuation ranges, sub-sector demand trends, regulatory and macro risks, and company-level comparisons of growth, margins, cash flow, balance sheet strength, and valuation.

Methodology notes

• Earnings reviewConsensus surprise analysis

  Compare the deviation of revenue, EPS, and full-year guidance versus market expectations.

  Most companies beat EPS expectations in the first quarter, but revenue was muted, and part of the EPS beat was driven by non-operating factors such as interest and taxes, so the report places more weight on earnings quality and forward guidance.

• Valuation analysisHistorical valuation range comparison

  Compare current P/E with the five-year valuation range and historical trading range.

  The sector's average next-fiscal-year P/E has fallen to around the lower end of the five-year range or below, and some high-quality companies trade below their historical ranges, supporting selective buying.

• Industry comparisonSub-sector cyclicality and company selection

  Split the view across sub-sectors such as CDMO, life science tools, diagnostics, healthcare services, pharmacies, packaging, and prosthetics/orthotics.

  The report does not treat the sector as a homogeneous asset class; instead, it differentiates allocation based on demand recovery, regulatory risk, customer concentration, cost pressure, and company execution.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Fresenius SE

  Sector favorite; Buy

  Strengths

  Strong momentum in Helios and Kabi, conservative 2026 guidance that may be beaten, and improving cash flow and ROIC.

  Weaknesses

  The share price is weighed down by uncertainty around German healthcare reform.

  Comparison

  Compared with Fresenius Medical Care, Fresenius SE has a more diversified portfolio and better growth and defensiveness.

  Risks

  The impact of German hospital reform may be worse than expected, and healthcare costs and inflation could rise.

• Lonza

  Sector favorite; Buy; CDMO top pick

  Strengths

  A global CDMO leader with resilient end markets, limited exposure to geopolitics and tariffs, a strong balance sheet, and improving cash flow and returns.

  Weaknesses

  Valuation rerating depends on continued reliable execution.

  Comparison

  The report prefers Lonza over Siegfried and Bachem, believing its growth and margins are not fully priced in.

  Risks

  If order confirmation is delayed, customer demand weakens, or sector de-rating continues, valuation recovery could be constrained.

• Sartorius

  Sector favorite; Buy

  Strengths

  A leader in bioprocess equipment and consumables, with stable recovery in consumables demand and expected return to sustainable double-digit adjusted EPS growth.

  Weaknesses

  The headline valuation is not low, and equipment demand recovery remains slow.

  Comparison

  Versus Merck KGaA and Tecan, the report prefers Sartorius for its consumables exposure and order momentum.

  Risks

  Weak demand for lab equipment in China, cautious large-capex spending, and a slower-than-expected recovery.

• Ottobock

  Sector favorite; Buy; Prosthetics & orthotics top pick

  Strengths

  A global leader in prosthetics and orthotics, with a rich product pipeline, conservative guidance, and growth and margin acceleration likely from the second quarter onward.

  Weaknesses

  A slower-than-expected start in the first quarter was anticipated.

  Comparison

  The report believes the current roughly 15x 2027E P/E does not fully reflect double-digit earnings growth.

  Risks

  Wars and conflicts can boost demand, but they also increase macro and supply-chain uncertainty.

• Diagnostics sector

  Cautious

  Strengths

  Qiagen is viewed as the relatively better name in the group.

  Weaknesses

  Almost all companies disappointed in the first quarter, affected by a weak respiratory season, subdued hospital capex, lower migration-testing volumes, structural changes in China, and supply-chain disruptions.

  Comparison

  The report sees Diasorin as having the highest downside risk, and it still trades at a 15-30% premium to bioMérieux and Qiagen.

  Risks

  Most guidance depends on a meaningful second-half improvement, so there is still downside risk if the recovery disappoints.

• Redcare Pharmacy

  Constructive; Buy

  Strengths

  A strong first quarter for the online pharmacy, an improving regulatory environment, and higher prescription-pharmacy reimbursement that should support earnings.

  Weaknesses

  The industry still needs to prove a full-year guidance raise and earnings delivery.

  Comparison

  The report is positive on Redcare and prefers it over DocMorris; DocMorris has financing uncertainty, while Galenica's valuation is rich.

  Risks

  Regulatory changes, funding costs, and intensifying competition could affect the earnings path.

Key data

• EPS beat magnitudeAverage +7.0%, median +6.5%Most companies delivered EPS beats, but some were driven by lower interest expense and taxes.
• Revenue deviationAverage -0.6%, median +0.3%Revenue was broadly in line with or slightly below expectations, and demand trends remain mixed.
• Change in full-year 2026 guidance13 reaffirmed, 5 cut, 3 raisedGuidance revisions were skewed negative, showing management teams remain cautious.
• Sector valuationNext FY P/E around 17-19xBelow the roughly 20x lower end of the five-year valuation range, indicating depressed valuations.
• Earnings estimate revisions2026E and 2027E adjusted net income index fell to around 0.84-0.85Revisions have continued downward from early 2025 through April 2026, indicating weak earnings estimate momentum.
• Fresenius SE valuationAbout 10x 2027E P/EThe report believes valuation does not fully reflect the defensive end markets, high-single-digit EPS growth, and improving cash flow.
• Lonza valuationAbout 22x 2027E P/EBelow its historical range of about 25-38x, which the report sees as offering an entry opportunity.
• Sartorius valuationAbout 33x 2027E P/EAt the low end of its historical range of about 33-55x, supported by mid-teens EPS growth.
• Ottobock valuationAbout 15x 2027E P/EThe report believes this does not fully reflect sustained double-digit earnings growth and the product cycle.

Impact & implications

For investors, the opportunity in European medical technology and life sciences lies not in a confirmed full recovery, but in the asymmetric rerating potential created by low valuations, light positioning, and low expectations. Portfolio allocation should lean toward companies with stronger execution, improving cash flow, solid balance sheets, more defensive end-demand, and valuations below historical ranges; meanwhile, investors should avoid companies that still depend on a significant second-half improvement, face regulatory or customer-concentration risks, or need to rebuild investor trust.

Risks

• A prolonged conflict in the Middle East that drives inflation could once again pressure sector valuations and margins.
• Investors may need more than one quarter of stable signs before re-engaging meaningfully.
• Consensus adjusted EPS for 2026 and 2027 is still being revised down, and earnings estimate momentum has not yet turned positive.
• China demand recovery may be slower than expected, especially in lab equipment, ophthalmology, and imaging-related markets.
• Tariffs, FX, and rising input costs may erode margins.
• Some companies face regulatory, customer concentration, financing, accounting investigation, or governance risks.

What to watch

• Whether second-quarter 2026 results can sustain EPS stability and improve revenue momentum.
• Whether consensus EPS revisions stop trending down and begin to edge higher.
• The impact of German healthcare reform on Fresenius and the continued momentum in Helios and Kabi.
• Order confirmation, capacity utilization, and reshoring demand at Lonza, Siegfried, and Bachem.
• Consumables orders, equipment demand, and the pace of recovery in China for Sartorius and Merck KGaA.
• Whether diagnostics companies can deliver on the assumed second-half improvement, especially Qiagen, Diasorin, and bioMérieux.
• Whether growth and margins at Ottobock accelerate after the second quarter, and progress on new product launches.
• The impact of inflation, tariffs, FX, and the Middle East conflict on costs and supply chains.